

Appendix B

Acknowledgments

OTA wishes to thank the Pharmaceutical R&D: Costs, Risks and Rewards Advisory Panel, its workshop participants, contractors, and the individuals and organizations listed below for their assistance over the course of this study. OTA also wishes to express appreciation to those who provided advice and information for its background paper, *Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease*. These individuals and organizations do not necessarily approve, disapprove, or endorse this report. OTA assumes full responsibility for the report and the accuracy of its content.

Lois Adams
Office of Legislative Affairs
U.S. Food and Drug Administration
Rockville, MD

Reid Adler
Office of Technology Transfer
U.S. National Institutes of Health
Bethesda, MD

Gwynn C. Akin
Public Policy
Syntex (USA) Inc.
Palo Alto, CA

Fredrik Andersson
Battelle MEDTAP Europe
Battelle Institute, Ltd.
London, England

Naomi Aronson
Technology Evaluation
Blue Cross Blue Shield Association
Chicago, IL

Carolyn Asbury
Health and Human Services
The Pew Charitable Trusts
Philadelphia, PA

Wade M. Aubrey
Blue Cross Blue Shield of California
San Francisco, CA

Wiltse Bailey
Washington, DC

P. Etienne Barral
Rhone-Poulenc Rorer
Antony, France

Norman Barton
Clinical Investigation Section
National Institute of Neurological Disorders
and Strokes
Bethesda, MD

Michael Beatrice
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
Rockville, MD

David W. Beier
Government Affairs
Genentech, Inc.
Washington, DC

Leslie Z. Benet
Department of Pharmacy
University of California
San Francisco, CA

Ernst Beutler
Department of Molecular and
Experimental Medicine
Scripps Research Institute
La Jolla, CA

Douglas W. Bitz
Sandoz Research Institute:
Sandoz Pharmaceuticals Corporation
East Hanover, NJ

Carla Bodaghi
U.S. Health Care Financing Administration
Washington, DC

Charles Booth
Office Payment Policy
U.S. Health Care Financing Administration
Baltimore, MD

Alan Blustin
Bureau of Labor Statistics
U.S. Department of Labor
Washington, DC

David Blumenthal
Medical Practices Evaluation Center
Massachusetts General Hospital
Boston, MA

Lawrence Brenkus
Arthur D. Little, Inc.
Cambridge, MA

John Brosan
Office of General Counsel
U.S. General Accounting Office
Washington, DC

Julie Cantor
Human Resources Division
U.S. General Accounting Office
Washington, DC

Douglas L. Cocks
Corporate Affairs
Eli Lilly and Company
Indianapolis, IN

Karen Cohen
National Gaucher's Foundation
Gaithersburg, MD

Joseph Collier
Department of Pharmacology **and**
Clinical Pharmacology
St. Georges Hospital Medical School
London, England

Paul Coppinger
Office of Planning and Evaluation
U.S. Food and Drug Administration
Rockville, MD

Pedro **Cuatrecasas**
Pharmaceutical Research Division
Warner-Lambert Company
Ann Arbor, MI

Joan M. Curran
Merck and Company, Inc.
Rahway, NJ

Bruce Cwalina
Springfield, VA

Patricia M. Danzon
School of Business
University of Pennsylvania
Philadelphia, PA

Alfred B. Engleberg
Greenwich, CT

Alain Enthoven
School of Business
Stanford University
Palo Alto, CA

David Evans
World Health Organization
Geneva, Switzerland

Dee Fensterer
Generic Pharmaceutical Industry Association
New York, NY

Franklin Fisher
School of Management
Massachusetts Institute of Technology
Cambridge, MA

Scott D. Freedman
Pharmaceutical Division
Miles, Inc.
West Haven, CT

Jesse Friedman
Chevy Chase, MD

Steven Garber
Rand Corporation
Santa Monica, CA

Kevin Gaynor
Price Waterhouse, Inc.
New York, NY

William Glaser
School of Management and Urban Policy
New School for Social Research
New York, NY

Sarah Glavin
Human Resources Division
U.S. General Accounting Office
Washington, DC

Martin Glick
Genentech, Inc.
San Francisco, CA

Gregory Grabowski
Children's Hospital Medical Center
University of Cincinnati Medical Center
Cincinnati, OH

Henry G. Grabowski
Department of Economics
Duke University
Durham, NC

Stephen C. Groft
Office of Science Policy and Legislation
U.S. National Institutes of Health
Bethesda, MD

David Gross
Human Resources Division
U.S. General Accounting Office
Washington, DC

Charles Grudzinskas
Medications Development Division
U.S. National Institute on Drug Abuse
Rockville, MD

Marlene E. Haffner
Orphan Products Development
U.S. Food and Drug Administration
Rockville, MD

Ronald Hansen
School of Business Administration
University of Rochester
Rochester, NY

Edward Haas
Office of Planning and Evaluation
U.S. Food and Drug Administration
Rockville, MD

Jody Hessen
Pharmacy, Policy, and Education
Aetna
Minneapolis, MN

Michelle Hiltebeitel
IMS America
Plymouth Meeting, PA

Peter Barton Hutt
Covington & Burling
Washington, DC

David Jackson
Janssen Pharmaceuticals, Inc.
Piscataway, NJ

David C. Jones
Chapel Hill, NC

Robert Kaplan
School of Business Administration
Harvard University
Boston, MA

David Karlin
Institute of Clinical Medicine
Syntex Research
Palo Alto, CA

Alison Keith
U.S. Pharmaceuticals
Pfizer, Inc.
New York, NY

John V. Kelsey
Office of Orphan Products Development
U.S. Food and Drug Administration
Rockville, MD

William Kennedy
Drug Regulatory Affairs
ICI Pharmaceuticals Group
Wilmington, DE

Christian L. Khung
Policy Research and Development
Blue Cross and Blue Shield of Massachusetts
North Quincy, MA

Richard Kinny
Legislative Affairs
Schering-Plough Corporation
Washington, DC

Mary C. Knipmeyer
Office of Women Services
U.S. Substance Abuse and Mental
Health Administration
Rockville, MD

Neil Kran
Internal Revenue Service
U.S. Department of the Treasury
New York, NY

Jacques Krasny
Bogart, Delafield, and Ferrier, Inc.
Morristown, NJ

Nancy J.W. Lewis
Institute for Pharmaceutical Economics
Philadelphia College of Pharmacy and Science
Philadelphia, PA

Harold S. Luft
Institute for Health Policy Studies
University of California
San Francisco, CA

Evan Marks
MEDCO Containment Services
Montvale, NJ

Kathleen McAvoy
Office of Planning and Evaluation
U.S. Food and Drug Administration
Rockville, MD

Jack McConnell
Hilton Head Island, SC

Robert T. McDonough
Public Policy Planning
The Upjohn Company
Kalamazoo, MI

Peter Merrill
Washington National Tax Service
Price Waterhouse, Inc.
Washington, DC

Gerald Meyer
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Rockville, MD

Abbey Meyers
National Organization for Rare Disorders
New Fairfield, CT

Ann Meyers
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Rockville, MD

Dann M. Michols
National Pharmaceutical Strategy
Ottawa, Ontario

Robert R. Miller
International Finance Corporation
Washington, DC

Andrew Mitchell
Pharmaceutical Evaluation
Department of Health Housing and
Community Services
Canberra, Australia

John Moeller
Center for General Health Services
Intramural Research
U.S. Agency for Health Care Policy and Research
Rockville, MD

Melissa Moncavage
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Rockville, MD

Lee Mortenson
Association of Community Cancer Centers
Rockville, MD

Dennis Mueller
Department of Economics
University of Maryland
College Park, MD

Michael Murray
Office of the General Counsel
U.S. House of Representatives
Washington, DC

Jane S. Myers
Patent and Trademark Office
U.S. Department of Commerce
Washington, DC

Maven Myers
Department of Pharmacy
Philadelphia College of Pharmacy and Science
Philadelphia, PA

John O'Hare
Joint Committee on Taxation
U.S. Congress
Washington, DC

Jonathan Peck
Institute for Alternative Futures
Alexandria, VA

Gary Persinger
Health Care Systems Division
Pharmaceutical Manufacturers Association
Washington, DC

Tim Proctor
Office of General Counsel
Merck & Company, Inc.
Rahway, NJ

Lisa Raines
Government Relations
Industrial Biotechnology Association
Washington, DC

Jonathan Ratner
Human Resources Division
U.S. General Accounting Office
Washington, DC

James W. Rayburn
Regulatory Affairs
Bristol-Myers Squibb Company
Evansville, IN

Larry Reed
Medicaid Non-Institutional Payment Policy Branch
U.S. Health Care Financing Administration
Baltimore, MD

Heinz Redwood
Suffolk, England

Michael R. Reich
School of Public Health
Harvard University
Boston, MA

Bryan G. Reuben
Department of Chemical Engineering
Southbank Polytechnic
London, England

Gerald Robertson
Department of Policy, Planning and Evaluation
Patented Medicine Prices Review Board
Ottawa, Ontario

Deborah Regal
Alpha Center
Washington, DC

James B. Russo
Government and Public Policy
Smithkline Beecham

Gerald L. Salamon
Department of Accounting
Indiana University
Bloomington, IN

Jeffrey Sanders
Office of Legislation and Policy
U.S. Health Care Financing Administration
Washington, DC

Alice Sapienza
School of Public Health
Harvard University
Boston, MA

Janet Scheren
National Wholesale Druggists Association
Alexandria, VA

Stuart Schweitzer
Department of Health Services
University of California
Los Angeles, CA

James Shuttinga
Office of the Director
U.S. National Institutes of Health
Bethesda, MD

Richard Sweeney
School of Business Administration
Georgetown University
Washington, DC

Max W. Talbott
Lilly Research Laboratories
Eli Lilly and Company
Indianapolis, IN

Alison Taunton-Rigby
Biotherapeutics
Genzyme Corporation
Cambridge, MA

Albert Teich
Directorate for Science and Policy Programs
American Association for the Advancement of Science
Washington, DC

Henri Termeer
Genzyme Corporation
Cambridge, MA

Charles E. Van Horn
Patent and Trademark Office
U.S. Department of Commerce
Washington, DC

Jon E. Villaume
Drug Regulatory Affairs
Roche Pharmaceuticals
Nutley, NJ

Stuart Walker
Centre for Medicines Research
Surrey, England

Andrew J. Webster, Ph.D.
Faculty of Humanities, Arts, and Education
Anglia University
Cambridge, England

Roy Widdus
National Commission on AIDS
Washington, DC

Sidney Wolfe
Health Research Group
Washington, DC

Robert Wren
Bureau of Eligibility, Coverage and Reimbursement
U.S. Health Care Financing Administration
Baltimore, MD

James P. Yee
Institute of Clinical Medicine
Syntex Research
Palo Alto, CA

Aki Yoshikawa
Stanford University
Palo Alto, CA

OTA also acknowledges the assistance of individuals from the following pharmaceutical companies, without whom neither the survey on the size of clinical trials nor OTA's on-site interviews of pharmaceutical executives would have been possible.

Abbott Laboratories
Abbott Park, IL

Bristol-Myers Squibb Company
Princeton, NJ

Cetus Corporation
Emeryville, CA

Ciba-Geigy Corporation
Summit, NJ

Genentech, Inc.
San Francisco, CA

Hoffman-La Roche, Inc.
Nutley, NJ

Hoechst-Roussel Pharmaceuticals, Inc.
Somerville, NJ

ICI Pharmaceuticals Group
Wilmington, DE

Janssen Pharmaceutical, Inc.
Piscataway, NJ

Lederle Laboratories
Pearl River, NY

Eli Lilly and Company, Inc.
Indianapolis, IN

Mead Johnson & Company
Evansville, IN

Merck and Company, Inc.
Rahway, NJ

Miles, Inc.
West Haven, CT

Norwich Eaton Pharmaceuticals, Inc.
Norwich, NY

Parke-Davis
Ann Arbor, MI

Pfizer, Inc.
New York, NY

The R.W. Johnson Pharmaceutical
Research Institute
Raritan, NJ

Sandoz Pharmaceuticals Corporation
Hanover, NJ

Schering-Plough Corporation
Kenilworth, NJ

SmithKline Beecham Corporation
Philadelphia, PA

Syntex (U.S.A.), Inc.
Palo Alto, CA

Takeda U. S. A., Inc.
New York, NY

TAP Pharmaceuticals, Inc.
Deerfield, IL

The Upjohn Company
Kalamazoo, MI

Wyeth-Ayerst Research
Philadelphia, PA